About
News, Events & Presentations
Press Releases | Events Calendar | Presentations

Keyword Search
 
2017 | 2016 | 2015 | 2014
DateTitle 
12/11/17Fibrocell Announces Closing of $10.5 Million Underwritten Public OfferingPrinter Friendly Version
12/07/17Fibrocell Announces Pricing of $10.5 Million Underwritten Public OfferingPrinter Friendly Version
11/13/17Fibrocell Reports Third Quarter 2017 Financial Results and Recent HighlightsPrinter Friendly Version
11/06/17Fibrocell to Host Conference Call and Webcast on Monday, November 13, 2017 to Discuss Third Quarter 2017 Financial Results and Recent Operational HighlightsPrinter Friendly Version
10/02/17Fibrocell to Present at 2017 Cell & Gene Meeting on the MesaPrinter Friendly Version
09/26/17Fibrocell Reports Interim Results of Phase 1/2 Clinical Trial of FCX-007 Gene Therapy for Recessive Dystrophic Epidermolysis BullosaPrinter Friendly Version
09/05/17Fibrocell to Present at Rodman & Renshaw 19th Annual Global Investment Conference and Global Genes’ 2017 RARE Patient Advocacy SummitPrinter Friendly Version
08/09/17Fibrocell Reports Second Quarter 2017 Financial Results and Recent HighlightsPrinter Friendly Version
08/03/17Fibrocell to Present at Canaccord Genuity 37th Annual Growth ConferencePrinter Friendly Version
08/02/17Fibrocell to Host Conference Call and Webcast on Wednesday, August 9, 2017 to Discuss Second Quarter 2017 Financial Results and Recent Operational HighlightsPrinter Friendly Version
06/12/17Fibrocell Receives Rare Pediatric Disease Designation from FDA for FCX-013 for Treatment of Localized SclerodermaPrinter Friendly Version
06/08/17Fibrocell Completes Dosing of First Cohort in Phase 1/2 Clinical Trial of FCX-007 Gene Therapy for Treatment of Recessive Dystrophic Epidermolysis BullosaPrinter Friendly Version
05/17/17Fibrocell to Present at Inaugural Cell & Gene Exchange 2017Printer Friendly Version
05/10/17Fibrocell Reports First Quarter 2017 Financial Results and Recent Operational HighlightsPrinter Friendly Version
05/09/17Fibrocell and Intrexon Announce Two Oral Presentations at the 20th Annual Meeting of the American Society of Gene & Cell TherapyPrinter Friendly Version
05/08/17Fibrocell Announces Data Safety Monitoring Board Recommends Continuation of Phase 1/2 Clinical Trial of FCX-007 for Treatment of Recessive Dystrophic Epidermolysis BullosaPrinter Friendly Version
05/03/17Fibrocell to Host Conference Call and Webcast on Wednesday, May 10, 2017 to Discuss First Quarter 2017 Financial Results and Recent Operational HighlightsPrinter Friendly Version
04/13/17Fibrocell to Present at 7th Annual World Orphan Drug Congress USA 2017 and 5th Annual Cell & Gene Therapy Investor DayPrinter Friendly Version
03/28/17Fibrocell Regains Compliance with NASDAQ Listing RequirementsPrinter Friendly Version
03/10/17Fibrocell Announces One-for-Three Reverse Stock SplitPrinter Friendly Version
03/09/17Fibrocell Reports 2016 Financial Results and Recent Operational HighlightsPrinter Friendly Version
03/07/17Fibrocell to Host Conference Call and Webcast on Thursday, March 9, 2017 to Discuss 2016 Financial Results and Recent Operational HighlightsPrinter Friendly Version
03/07/17Fibrocell Announces Convertible Preferred Stock Financing for $8.0 MillionPrinter Friendly Version
02/23/17Fibrocell Announces Dosing of First Patient in Phase I/II Clinical Trial of FCX-007 Gene Therapy for Treatment of Recessive Dystrophic Epidermolysis BullosaPrinter Friendly Version
01/05/17Fibrocell Announces FDA Fast Track Designation of FCX-007 for Treatment of Recessive Dystrophic Epidermolysis BullosaPrinter Friendly Version



Printer Friendly Version E-mail this page RSS E-mail Alerts Download Financial Tear Sheet